GLPG Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 121331 min ago

@ $39.44

Wydano: 12 vas. 2024 @ 16:30

Zwrot: -25.28%

Poprzedni sygnał: vas. 9 - 16:30

Poprzedni sygnał: Sprzedaż

Zwrot: 0.23 %

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 23:00):

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need...

Stats
Dzisiejszy wolumen	68 626.00
Średni wolumen	127 920
Kapitalizacja rynkowa	1.94B
EPS	$0 ( 2024-05-02 )
Następna data zysków	( $-0.0800 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-491.17
ATR14	$0.0260 (0.09%)

Wolumen Korelacja

Długi: 0.08 (neutral)

Krótki: -0.75 (moderate negative)

Signal:(52.473) Neutral

Galapagos NV Korelacja

10 Najbardziej pozytywne korelacje
HCDIP	0.959
HTLD	0.958
SPTN	0.958
EMBC	0.956
SHEN	0.955
BIGC	0.951
PEAR	0.95
AMPH	0.949
AKTX	0.948
PRTS	0.945

10 Najbardziej negatywne korelacje
PPC	-0.962
PNTG	-0.959
MSAC	-0.959
KAII	-0.958
AEAC	-0.956
TZPS	-0.954
SWAV	-0.953
BIOT	-0.952
RZLT	-0.952
VITL	-0.952

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Galapagos NV Korelacja - Waluta/Towar

0.15
( neutral )

0.22
( neutral )

0.66
( moderate )

0.69
( moderate )

0.20
( neutral )

-0.35
( neutral )

Galapagos NV Finanse

Annual	2023
Przychody:	$239.72M
Zysk brutto:	$239.70M (99.99 %)
EPS:	$3.21

FY	2023
Przychody:	$239.72M
Zysk brutto:	$239.70M (99.99 %)
EPS:	$3.21

FY	2022
Przychody:	$505.28M
Zysk brutto:	$493.20M (97.61 %)
EPS:	$-3.32

FY	2021
Przychody:	$484.85M
Zysk brutto:	$483.22M (99.66 %)
EPS:	$-1.580

Financial Reports:

No articles found.

Galapagos NV

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.